psalexa
P&S Market Research - A market research firm

Poliomyelitis Therapeutics Pipeline Analysis

Poliomyelitis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11267
Available Format:

Poliomyelitis is an infectious disease which is caused by viruses (polioviruses) that belongs to picornaviridae family. Poliomyelitis generally affects nerves and can leads to total paralysis. The disease can be symptomatized by gastroenteritis, malaise, respiratory illness, and paralysis. Poliomyelitis is classified into three categories paralytic poliomyelitis, nonparalytic poliomyelitis, and abortive poliomyelitis. Polioviruses can be spread by direct contact with the infected person, contact with infected faeces, and contact with infected phlegm or mucus. The spread is more in areas with poor hygiene. Takeda Pharmaceutical Company Limited is in the process of developing sabin-based inactivated poliomyelitis vaccine for the treatment of poliomyelitis. Boryung Pharmaceutical Co., Ltd is in the process of developing DTaP-IPV combination vaccine for the treatment of poliomyelitis. Some of the companies and universities having the pipeline of poliomyelitis include Boryung Pharmaceutical Co., Ltd, Serum Institute of India Pvt. Ltd., Grifols Biologicals Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry